As per the previous agreement, both the firms collaborated for the commercialization of Sinclair’s dermatology brands in eleven Asia Pacific countries.
Under an agreement, the companies have launched atopic dermatitis treatment, Atopiclair in Hong Kong, Malaysia, Singapore and India and Papulex, for management and maintenance of mild to moderate acne, in Taiwan, India and Hong Kong.
Launches are scheduled in a further four countries by calendar year-end.
Sinclair CEO Chris Spooner said they believe that the Invida partnership offers a template for future Sinclair IS commercial relationships in other regions.